TY  - JOUR
AU  - Rudà, Roberta
AU  - Capper, David
AU  - Waldman, Adam D
AU  - Pallud, Johan
AU  - Minniti, Giuseppe
AU  - Kaley, Thomas J
AU  - Bouffet, Eric
AU  - Tabatabai, Ghazaleh
AU  - Aronica, Eleonora
AU  - Jakola, Asgeir S
AU  - Pfister, Stefan
AU  - Schiff, David
AU  - Lassman, Andrew B
AU  - Solomon, David A
AU  - Soffietti, Riccardo
AU  - Weller, Michael
AU  - Preusser, Matthias
AU  - Idbaih, Ahmed
AU  - Wen, Patrick Y
AU  - van den Bent, Martin J
TI  - Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors
JO  - Neuro-Oncology
VL  - 24
IS  - 12
SN  - 1522-8517
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DKFZ-2022-01641
SP  - 2015-2034
PY  - 2022
N1  - 2022 Dec 1;24(12):2015-2034
AB  - In the new WHO 2021 Classification of CNS Tumors the chapter “Circumscribed astrocytic gliomas, glioneuronal and neuronal tumors” encompasses several different rare tumor entities, which occur more frequently in children, adolescents and young adults. The Task Force has reviewed the evidence of diagnostic and therapeutic interventions, which is low particularly for adult patients, and draw recommendations accordingly. Tumor diagnosis, based on WHO 2021, is primarily performed using conventional histological techniques; however, molecular workup is important for differential diagnosis, in particular DNA methylation profiling for the definitive classification of histologically unresolved cases. Molecular factors are increasingly of prognostic and predictive importance. MRI finding are non specific, but for some tumors are characteristic and suggestive. Gross total resection, when feasible, is the most important treatment in terms of prolonging survival and achieving long-term seizure control. Conformal radiotherapy should be considered in grade 3 and incompletely resected grade 2 tumors. In recurrent tumors reoperation and radiotherapy, including stereotactic radiotherapy, can be useful. Targeted therapies may be used in selected patients: BRAF and MEK inhibitors in pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and gangliogliomas when BRAF altered, and mTOR inhibitor everolimus in subependymal giant cells astrocytomas .Sequencing to identify molecular targets is advocated for diagnostic clarification and to direct potential targeted therapies.
LB  - PUB:(DE-HGF)16
C6  - pmid:35908833
DO  - DOI:10.1093/neuonc/noac188
UR  - https://inrepo02.dkfz.de/record/180916
ER  -